Under construction – not a live service
Sign in
Taking peopleNo phase

Comparative Assessment of Sleep Positive Airway Pressure Modalities (CASPAM)

Key facts

Who runs it
National University of Malaysia
Where
Malaysia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
50 people, planned
Started
1 Sept 2024
Expected to end
1 Jan 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CPAP Airsense 10 vs Air-Mini
Record updated
14 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Aged ≥ 18 years
  • Patients diagnosed with moderate to severe OSA (based on AHI classification from sleep study performed)
  • Patients who are able to understand and answer the questionnaire given

Who cannot take part

  • Patients who had underlying Obesity Hypoventilation Syndrome (OHS)
  • Patients who had underlying co-morbidities that worsen apnea symptoms, such as congestive cardiac failure, active malignancy, narcolepsy, active alcohol or drug abuse, treatment-refractory dementia, psychotic illness and active use of drugs that disturb the sleep architecture (i.e hypnotics or stimulants of central nervous system)
  • Patients who are unable to give consent to the study
  • Patients who have been diagnosed with OSA and already on CPAP machine

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Obstructive sleep apnea (OSA) has been one of the topmost global health problems. It is an underdiagnosed disease which have a huge burden on healthcare if left untreated. Almost 80-90% of adults are underdiagnosed of OSA Obesity primarily is one of the supreme risk factors for developing OSA. Globally, obesity cases have risen affecting almost two billion people. According to National Health and Morbidity Survey (NHMS) 2019, 1 in 2 adults in Malaysia were overweight or obese. Report from World Obesity Atlas 2023 predicts that adult obesity will rise 4.7% annually from 2020 - 2035, while child obesity will increase by 5.3% per year over similar timeline. Overweight individuals will have a significant economic impact on Malaysia's Gross Domestic Product (GDP) by 2035 by 2.8% which is estimated to be about RM 3.2 trillion.

Read full original descriptionShow less

Sequalae of OSA is divided into two (cardiovascular-metabolic effect and neurocognitive effect). This group of patients are at high risk of developing hypertension, insulin resistance, dyslipidemia which then leads to pulmonary hypertension and heart failure. More importantly, from the neurocognitive point of view, persistent sleep deprivation will lead to poor concentration, impaired memory, personality changes affecting overall self-performance which can lead to depression and compromising safety as they have higher risk of work-related accidents.

The 2 groups in the trial

  • CPAP Airsense 10Existing treatment, for comparison

    Participants in CPAP Airsense 10

    Treatment: CPAP Airsense 10 vs Air-Mini

  • CPAP AIr-MiniExisting treatment, for comparison

    Participants in CPAP AIr-Mini

    Treatment: CPAP Airsense 10 vs Air-Mini

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comparative Assessment of Sleep Positive Airway Pressure Modalities (CASPAM) Trial: Conventional CPAP (AirSense 10) Versus Portable CPAP (AirMini) in Patients With Obstructive Sleep Apnea-A Randomized Crossover Study of User Preference
Record updated
14 July 2026